基于高密度脑电的不同麻醉药物老年患者的意识度量

注册号:

Registration number:

ChiCTR2300070312 

最近更新日期:

Date of Last Refreshed on:

2026-03-03 09:45:42 

注册时间:

Date of Registration:

2023-04-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于高密度脑电的不同麻醉药物老年患者的意识度量

Public title:

Measurement of consciousness in elderly patients with different anesthetic drugs based on high-density EEG

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于高密度脑电的不同麻醉药物老年患者的意识度量

Scientific title:

Measurement of consciousness in elderly patients with different anesthetic drugs based on high-density EEG

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王甜 

研究负责人:

李民 

Applicant:

Tian Wang 

Study leader:

Min Li 

申请注册联系人电话:

Applicant telephone:

+86 10 8226 7230

研究负责人电话:

Study leader's
telephone:

+86 10 8226 7272

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

18813019560@163.com

研究负责人电子邮件:

Study leader's E-mail:

liminanesth@aliyun.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

北京大学第三医院

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区花园北路49号

研究负责人通讯地址:

北京市海淀区花园北路49号

Applicant address:

49 Huayuan Road North, Haidian District, Beijing

Study leader's address:

49 Huayuan Road North, Haidian District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京大学第三医院

Applicant's institution:

Peking University Third Hospital

研究负责人所在单位:

北京大学第三医院

Affiliation of the Leader:

Peking University Third Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2023)医伦审第(038-01)号; (2023)医伦审第(038-02)号; (2023)医伦审第(038-03)号;

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京大学第三医院医学科学研究伦理委员会

Name of the ethic committee:

Ethics Committee of Peking University Third Hospital Medical Science Research

伦理委员会批准日期:

Date of approved by ethic committee:

2023-02-02 00:00:00

伦理委员会联系人:

洪雪

Contact Name of the ethic committee:

Xue Hong

伦理委员会联系地址:

北京市海淀区花园北路49号

Contact Address of the ethic committee:

49 Huayuan Road North, Haidian District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8226 7230

伦理委员会联系人邮箱:

Contact email of the ethic committee:

18813019560@163.com

研究实施负责(组长)单位:

北京大学第三医院

Primary sponsor:

Peking University Third Hospital

研究实施负责(组长)单位地址:

北京市海淀区花园北路49号

Primary sponsor's address:

49 Huayuan Road North, Haidian District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

海淀区

Country:

China

Province:

Beijing

City:

Haidian District

单位(医院):

北京大学第三医院

具体地址:

花园北路49号

Institution
hospital:

Peking University Third Hospital

Address:

49 Huayuan Road North

经费或物资来源:

中国科技部科技创新2030——“脑科学与类脑研究”重大项目:全麻诱发的意识水平变化规律及调控研究(2021ZD0204304)

Source(s) of funding:

Science and Technology Innovation 2030: Major project of "Brain Science and Brain-inspired Research": Research on the patterns and regulation of consciousness level changes induced by general anesthesia (2021ZD0204304).

研究疾病:

N/A  

Target disease:

N/A

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

拟以功能连接为基础,结合图论,度量麻醉过程中的脑网络变化规律,从而用于构建有效的麻醉监测体系。  

Objectives of Study:

To measure the changes of brain network during anesthesia, so as to construct an effective anesthesia monitoring system.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. BMI<18,或>30kg/m2 2. 药物滥用史; 3. 试验药物如局麻药、丙泊酚、右美托咪定过敏史,或鸡蛋过敏史; 4. 术前心动过缓或存在传导阻滞; 5. 神经系统疾病; 6. 长期使用精神活性药物; 7. 不能配合完成评估或问卷调查等患者; 8. 拒绝参加本研究。

Exclusion criteria:

1. BMI< 18, or > 30kg/m2; 2. History of drug abuse; 3. History of allergy to test drugs such as local anesthetic, propofol, dexmedetomidine, or egg allergy; 4. Preoperative bradycardia or conduction block; 5. Nervous system diseases; 6. Long-term use of psychoactive drugs; 7. Patients who could not cooperate to complete the assessment or questionnaire survey; 8. Refused to participate in the study.

研究实施时间:

Study execute time:

From 2023-09-11 00:00:00 To 2024-05-20 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-09-11 00:00:00 To 2024-05-13 00:00:00

干预措施:

Interventions:

组别:

丙泊酚组

样本量:

30

Group:

Propofol group

Sample size:

干预措施:

镇静采用靶控输注(TCI)方式给药。丙泊酚通过Marsh模型给药,起始效应部位浓度为 1.0 μg/mL,每 5 分钟递增 0.5 μg/mL,直至患者失去反应。

干预措施代码:

Intervention:

Sedation was delivered using target-controlled infusion (TCI). Propofol was delivered via the Marsh model, starting at an effect-site concentration of 1.0 μg/mL, with incremental of 0.5 μg/mL every 5 minutes until loss of responsiveness .

Intervention code:

组别:

右美托咪定组

样本量:

30

Group:

Dexmedetomidine group

Sample size:

干预措施:

镇静采用靶控输注(TCI)的方式进行。右美托咪定通过迪克模型给药,初始效应部位浓度为 0.5 纳克/毫升,每 5 分钟增加 0.2 纳克/毫升,直至达到患者失去反应。

干预措施代码:

Intervention:

Sedation was delivered using target-controlled infusion (TCI). Dexmedetomidine was administered using the Dyck model, beginning at an effect-site concentration of 0.5 ng/mL, with 0.2 ng/mL increments every 5 minutes until LOR.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学第三医院 

单位级别:

三甲 

Institution
hospital:

Peking University Third Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

原始脑电图

指标类型:

主要指标

Outcome:

Electroencephalogram, EEG

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

CAM谵妄评估

指标类型:

次要指标

Outcome:

CAM delirium assessment

Type:

Secondary indicator

测量时间点:

测量方法:

CAM 量表

Measure time point of outcome:

Measure method:

Confusion Assessment Method

指标中文名:

MoCA认知评估

指标类型:

次要指标

Outcome:

MoCA cognitive assessment

Type:

Secondary indicator

测量时间点:

测量方法:

蒙特利尔认知评估量表

Measure time point of outcome:

Measure method:

Montreal Cognitive Assessment, MoCA

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字由独立于本试验数据管理和统计分析执行的统计学家使用RedCap生成,采用1:1比例随机化。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random numbers were generated using RedCap, employing block randomization at a 1:1 ratio, by a statistician independent of data management and statistical analysis execution for this trial.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

患者、外科医生和负责随访和统计分析的人员对组分配不知情。

Blinding:

Patients, surgeons, and personnel responsible for follow-up and statistical analysis were blinded to group allocation.

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究公开发表后可通过联系研究者liminanesth@aliyun.com 征得同意后使用。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The raw data and materials used and/or analyzed during the current study will be available upon request from the corresponding authors(liminanesth@aliyun.com) after publication.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-04-10 08:43:27